High purity factor IX and prothrombin complex concentrate (PCC): Pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC

Thrombosis and Haemostasis

Volumn 76, Issue 1, 1996, Pages 23-28

  Philippou, H ^a   Adami, A ^a   Lane, D A ^a   MacGregor, I R ^b   Tuddenham, E G D ^c   Lowe, G D O ^d   Rumley, A ^d   Ludlam, C A ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^c MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; PEPTIDE; PROTHROMBIN; PROTHROMBIN COMPLEX; THROMBIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HEMOPHILIA B; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOGENICITY;

EID: 0030035389     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650516     Document Type: Article

References (47)

1. Menache D. Prothrombin complex concentrates: clinical use. Ann New York Acad Sci 1981; 370: 747-56.
2. Thompson AR. Factor-IX concentrates for clinical use. Sem Thromb Hemost 1993; 19: 25-36.
3. Seremetis SV, Aledort LM. Congenital Bleeding Disorders - Rational Treatment Options. Drugs 1993; 45: 541-7.
4. Prowse C, Cash JD. The use of factor IX concentrates in man: a 9-year experience of Scottish concentrates in the South-East of Scotland. Br J Haemat 1981; 47: 91-104.
5. Lusher JM. Perspectives on the use of factor-IX complex concentrates in the treatment of bleeding in persons with acquired factor-VIII inhibition. Am J Med 1991; 91 Suppl 5a: S30-S34.
6. Aledort LM. Factor IX and thrombosis. Sc J Haemat 1977; Suppl. 30: 40-2.
7. Lusher JM. Prediction and management of adverse events associated with the use of factor-IX complex concentrates. Sem Hemat 1993; 30 Suppl 1: 36-40.
8. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor-VIII and factor-IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
9. Johnson AJ, Mathews RW, Fulton AJ Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors. Clin Haemat 1984; 13: 3-15.
10. Edwards CA, Pier MP, Chin S, Horowitz B. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 1987; 52: 53-9.
11. Menache D. New concentrates of factors VII, IX and X. Prog Clin Biol Res 1990; 324: 177-87.
12. Menache D, Behre HE, Orthner CL, Nunez H, Anderson HD. Triantaphyllopoulos DC, Kosow DP: Coagulation factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models. Blood 1984; 64: 1220-7.
13. Harrison J, Abildgaard C, Lazerson J, Culbertson R, Anderson G. Assessment of thrombogenicity of prothrombin complex concentrates in a porcine model. Thromb Res 1985; 38: 173-88.
14. Smith KJ. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals. Blood 1988; 72: 1269-77.
15. Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM. Human coagulation factor-IX - assessment of thrombogenicity in animal models and viral safety. J Lab Clin Med 1993; 121: 394-405.
16. MacGregor IR, Ferguson JM. McLaughlin LF, Burnouf T, Prowse CV. Comparison of high purity factor-IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity. Thromb Haemost 1991; 66: 609-613.
17. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor-IX concentrate. Br J Haemat 1991; 79: 606-11.
18. Goudemand J, Marey A, Caron C, Wibaut B, Mizon P. Clinical efficacy of a highly purified SD-treated factor IX concentrate prepared by conventional chromatography. Trans Med 1993; 3: 299-305.
19. Berntorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in-vivo properties of high purity factor-IX concentrates. Thromb Haemost 1993; 70: 768-73.
20. Santagostino E, Mannucci PM, Gringeri A. Tagariello G, Baudo F, Bauer KA, Rosenberg RD. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thromb Haemost 1994; 71: 737-40.
21. Thomas DP, Hampton KK, Dasani H, Lee CA, Giangrande PLF, Harman C, Lee ML, Preston FE. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haemat 1994; 87: 782-8.
22. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia-B patients after the infusion of a purified factor-IX concentrate. Blood 1990; 76: 2540-5.
23. Hampton KK, Makris M, Kitchen S, Preston FE. Potential thrombogenicity of heat-treated prothrombin complex concentrates in haemophilia-B. Blood Coag Fibrin 1991; 2: 637-41.
24. Kim HC, Matts, L, Eisele J, Czachur M, Saidi P. Monoclonal antibody-purified factor IX: comparative thrombogenicity to prothrombin complex concentrate. Sem Hemat 1991; 28 Suppl. 6: 15-9.
25. Middleton SM, Bennett IH, Smith JK. A therapeutic concentrate of coagulation factors II, IX and X from citrated. factor VIII-depleted plasma. Vox Sang 1973; 24: 441-56.
26. Littlewood JD, Dawes J, Smith JK, Feldman PA, Haddon ME, McQuillan TA, Foster. PR, Ferguson J, Prowse CV. Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs. Br J Haemat 1987; 65: 463-8.
27. Burnouf T, Michalski C, Goudemand M, Huart JJ. Properties of a highly purified human plasma factor IX: c therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-32.
28. Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, Smith KJ. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82: 3350-7.
29. (1+2). Thromb Haemost 1993; 70: 253-8.
30. ' 30. Collins P, Roderick A, Obrien D, Tuddenham E, O'Driscoll A, Chopra R, Goldstone A, Newland A. Factor VIIa and other haemostatic variables following bone marrow transplantation. Thromb Haemost 1994; 72: 28-32.
31. Philippou H, Adami A, Boisclair MD, Lane DA An ELISA for factor X activation peptide: Application to the investigation of thrombogenesis in cardiopulmonary bypass. Br J Haemat 1995; 90: 432-7.
32. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor-VIII and factor-IX. Thromb Haemost 1991; 6: 384-6.
33. Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, Tencate H, Kestin AS, Brettler DB, Rosenberg RD. Factor-IXa- Factor-VIIIaCell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood 1992; 79: 2039-47.
34. Kim HC, Mcmillan CW, White GC, Bergman GE, Horion MW, Saidi P. Purified factor-IX using monoclonal immunoaffmity technique - clinical trials in hemophilia-B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-575.
35. Goldsmith JC, Kasper CK, Blatt PM, Gomperts ED, Kessler CM, Thompson AR, Herring SW, Novak PL. Coagulation factor- IX - successful surgical experience with a purified factor-IX concentrate. Am J Hemat 1992; 40: 210-5.
36. Hampton KK, Preston FE, Lowe GDO, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haemat 1993; 84: 279-84.
37. Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 1990; 4: 25-40.
38. Shifman MA, Pizzo SV. The in-vivo metabolism of antithrombin III and antithrombin complexes. J Biol Chem 1982; 257: 3243-7.
39. Bauer KA, Broekmans AW, Bertina RM, Conard J, Horellou MH, Samama MM. Rosenberg RD. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988; 71: 1418-26.
40. Bauer KA, Kass BL, ten Gate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989; 74: 2007-15.
41. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor-IX is activated in-vivo by the tissue factor mechanism. Blood 1990; 76: 731-6.
42. Bauer KA. Laboratory markers of coagulation activation. Arch Path Lab Med 1993; 117: 71-7.
43. Boisclair MD, Philippou H, Lane DA. Thrombogenic mechanisms in the human - fresh insights obtained by immunodiagnostic studies of coagulation markers. Blood Coag Fibrin 1993; 4: 1007-21.
44. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia-A and hemophilia-B patients. Blood 1992; 80: 25-8.
45. Gitel S, Stephenson RC, Wessler S. In vitro and in vivo correlation of clotting protease activity: effect of heparin. Proc Natl Acad Sci USA 1977; 74: 3028-32.
46. Gray E, Tubbs J, Thomas S, Gates A, Boisclair M, Kemball-Cook MG, Barrowcliffe TW. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost 1995; 73: 675-9.
47. Hrinda ME, Huang C, Tarr GC, Weeks R, Feldman F, Schreiber AB. Preclinical studies of a monoclonal antibody-purified factor IX, Mononine. Sem Hemat 1991; 28 (Suppl 6): 6-14.